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Association Between Genetically Proxied Inhibition
of HMG-CoA Reductase and Epithelial Ovarian Cancer
James Yarmolinsky, MSc; Caroline J. Bull, PhD; Emma E. Vincent, PhD; Jamie Robinson, MSc;
Axel Walther, PhD, FRCP; George Davey Smith, DSc; Sarah J. Lewis, PhD; Caroline L. Relton, PhD;
Richard M. Martin, BMBS, PhD
IMPORTANCE Preclinical and epidemiological studies indicate a potential chemopreventive
role of statins in epithelial ovarian cancer risk.
OBJECTIVE To evaluate the association of genetically proxied inhibition of 3-hydroxy-3-
methylglutaryl coenzyme A (HMG-CoA) reductase (ie, genetic variants related to lower
function of HMG-CoA reductase, target of statins) with epithelial ovarian cancer among the
general population and in BRCA1/2 mutation carriers.
DESIGN, SETTING, AND PARTICIPANTS Single-nucleotide polymorphisms (SNPs) in HMGCR,
NPC1L1, and PCSK9 associated with low-density lipoprotein (LDL) cholesterol in a
genome-wide association study (GWAS) meta-analysis (N 196 475) were used to proxy
therapeutic inhibition of HMG-CoA reductase, Niemann-Pick C1-Like 1 (NPC1L1) and
proprotein convertase subtilisin/kexin type 9 (PCSK9), respectively. Summary statistics were
obtained for these SNPs from a GWAS meta-analysis of case-control analyses of invasive
epithelial ovarian cancer in the Ovarian Cancer Association Consortium (OCAC; N = 63 347)
and from a GWAS meta-analysis of retrospective cohort analyses of epithelial ovarian cancer
among BRCA1/2 mutation carriers in the Consortium of Investigators of Modifiers of BRCA1/2
(CIMBA; N = 31 448). Across the 2 consortia, participants were enrolled between 1973 and
2014 and followed up through 2015. OCAC participants came from 14 countries and CIMBA
participants came from 25 countries. SNPs were combined into multi-allelic models and
mendelian randomization estimates representing lifelong inhibition of targets were
generated using inverse-variance weighted random-effects models.
EXPOSURES Primary exposure was genetically proxied inhibition of HMG-CoA reductase and
secondary exposures were genetically proxied inhibition of NPC1L1 and PCSK9 and
genetically proxied circulating LDL cholesterol levels.
MAIN OUTCOMES AND MEASURES Overall and histotype-specific invasive epithelial ovarian
cancer (general population) and epithelial ovarian cancer (BRCA1/2 mutation carriers), measured
as ovarian cancer odds (general population) and hazard ratio (BRCA1/2 mutation carriers).
RESULTS The OCAC sample included 22 406 women with invasive epithelial ovarian cancer
and 40 941 control individuals and the CIMBA sample included 3887 women with epithelial
ovarian cancer and 27 561 control individuals. Median ages for the cohorts ranged from 41.5
to 59.0 years and all participants were of European ancestry. In the primary analysis,
genetically proxied HMG-CoA reductase inhibition equivalent to a 1-mmol/L (38.7-mg/dL)
reduction in LDL cholesterol was associated with lower odds of epithelial ovarian cancer
(odds ratio [OR], 0.60 [95% CI, 0.43-0.83]; P = .002). In BRCA1/2 mutation carriers,
genetically proxied HMG-CoA reductase inhibition was associated with lower ovarian cancer
risk (hazard ratio, 0.69 [95% CI, 0.51-0.93]; P = .01). In secondary analyses, there were no
significant associations of genetically proxied inhibition of NPC1L1 (OR, 0.97 [95% CI,
0.53-1.75]; P = .91), PCSK9 (OR, 0.98 [95% CI, 0.85-1.13]; P = .80), or circulating LDL
cholesterol (OR, 0.98 [95% CI, 0.91-1.05]; P = .55) with epithelial ovarian cancer.
CONCLUSIONS AND RELEVANCE Genetically proxied inhibition of HMG-CoA reductase was
significantly associated with lower odds of epithelial ovarian cancer. However, these findings
do not indicate risk reduction from medications that inhibit HMG-CoA reductase; further
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I n 2018 there were approximately 22 240 new cases ofovarian cancer diagnosed and 14 070 ovarian cancerdeaths in the United States.1 The prognosis for ovarian
cancer is generally poor because women typically present
with advanced disease and because there is a lack of early
detection tests.2 Given the limited success of screening strat-
egies, primary prevention of ovarian cancer may present an
important approach for reducing disease burden.
3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) re-
ductase inhibitors (statins) are low-density lipoprotein (LDL)
cholesterol–lowering drugs commonly prescribed for the pre-
vention and management of cardiovascular disease. Along with
their cardioprotective effects, statins have been hypoth-
esized to protect against development of several cancers, in-
cluding ovarian cancer.3 Laboratory studies have shown that
statins can induce apoptosis and inhibit tumor proliferation,
invasion, and metastasis.4-6 Observational studies have re-
ported lower rates of ovarian cancer among statin users com-
pared with nonusers.7,8 However, the clinical relevance of these
findings is unclear because of the unknown generalizability of
preclinical studies to humans and the susceptibility of con-
ventional observational analyses to residual confounding and
other biases.
Naturally occurring variation in genes encoding pharma-
cological targets can be used to proxy modulation of these
targets to examine the potential effects of their molecular
inhibition on disease outcomes (referred to as mendelian
randomization).9 Because germline genetic variants are
inherited approximately randomly and fixed at the time of
conception, analyses using variants as proxies for interven-
tion targets should be largely independent of confounding
and cannot be influenced by reverse causation.
A mendelian randomization approach was used to exam-
ine the association of the drug target of statins (HMG-CoA
reductase) with ovarian cancer and, in secondary analyses, to
examine the association of other lipid-lowering drug targets,
Niemann-Pick C1-Like 1 (NPC1L1; target of ezetimibe) and
proprotein convertase subtilisin/kexin type 9 (PCSK9; target
of PCSK9 inhibitors), along with LDL cholesterol directly,
with ovarian cancer.
Methods
Study Design and Data Sources
All studies contributing data to this analysis had the relevant
institutional review board approval from each country, in ac-
cordance with the Declaration of Helsinki, and all partici-
pants provided informed consent. Summary genetic associa-
tion data were obtained from case-control genome-wide
association study (GWAS) analyses of invasive epithelial ovar-
ian cancer from the Ovarian Cancer Association Consortium
(OCAC).10 OCAC data were also obtained for the following in-
vasive epithelial ovarian cancer histotypes: high-grade se-
rous carcinoma, low-grade serous carcinoma, endometrioid
carcinoma, mucinous ovarian cancer, and clear cell carci-
noma. The earliest start date for participants across OCAC stud-
ies was in 1976 and the latest date of follow-up was in 2015.
Summary data were also obtained from GWAS analyses
of epithelial ovarian cancer among BRCA1 (Entrez Gene: 672)
or BRCA2 (Entrez Gene: 675) mutation carriers from the Con-
sortium of Investigators of Modifiers of BRCA1/2 (CIMBA),
a retrospective cohort study.10 Participants were enrolled in
CIMBA between 1973 and 2014.
In OCAC and CIMBA, participants with 5% or more miss-
ing genotype calls were excluded; otherwise, missing geno-
type data were imputed. Additional details about the OCAC and
CIMBA analyses are available in the Supplement.
To generate genetic instruments to proxy HMG-CoA
reductase, NPC1L1, and PCSK9 and to proxy LDL cholesterol
levels directly, summary data were obtained from a GWAS
meta-analysis of LDL cholesterol levels in the Global Lipids
Genetics Consortium.11 To proxy HMG-CoA reductase,
5 single-nucleotide polymorphisms (SNPs) associated
with LDL cholesterol at genome-wide significance level
(P < 5.0 × 10−8) and within ±100 kb windows from the gene
region for HMGCR (Entrez Gene: 3156; encoding HMG-CoA
reductase) were obtained. To proxy NPC1L1, 3 SNPs associ-
ated with LDL cholesterol at genome-wide significance and
within ±100 kb from NPC1L1 (Entrez Gene: 29881; encoding
NPC1L1) were obtained. To proxy PCSK9, 11 SNPs associated
with LDL cholesterol at genome-wide significance and within
±100 kb from PCSK9 (Entrez Gene: 255738; encoding PCSK9)
were obtained. For each of these drug targets, SNPs used as
proxies were permitted to be in weak linkage disequilibrium
(r2 <0.20) with each other to increase the proportion of vari-
ance in each respective drug target explained by the instru-
ment, maximizing instrument strength.
To proxy LDL cholesterol levels, 76 independent (r2 <0.001)
SNPs associated with LDL cholesterol at genome-wide signifi-
cance level were obtained, irrespective of genomic position of
variants. SNP selection procedures across drug targets and LDL
cholesterol are presented in the Supplement.
Outcomes
The outcomes were overall and histotype-specific invasive epi-
thelial ovarian cancer (in the general population) and epithe-
lial ovarian cancer (in BRCA1/2 mutation carriers).
Key Points
Question Is there an association between genetically proxied
inhibition of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)
reductase and epithelial ovarian cancer in the general population
and among BRCA1/2 mutation carriers?
Findings In this case-control study that included 63 347
participants, genetically proxied HMG-CoA reductase inhibition
equivalent to a 1-mmol/L (38.7-mg/dL) reduction in low-density
lipoprotein cholesterol was significantly associated with lower odds
of epithelial ovarian cancer in the general population (odds ratio,
0.60) and among BRCA1/2 mutation carriers (hazard ratio, 0.69).
Meaning There was a significant association between genetically
proxied inhibition of HMG-CoA reductase and epithelial ovarian
cancer, but further research is needed to understand whether
there is a similar association with medications that inhibit
HMG-CoA reductase.
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Statistical Analysis
Mendelian randomization analysis assumes that the genetic
instrument used to proxy a risk factor (1) is associated with the
risk factor (“relevance”), (2) does not share a common cause
with the outcome (“exchangeability”), and (3) affects the out-
come only through the risk factor (“exclusion restriction”).
SNPs used to proxy each of the risk factors were matched
to ovarian cancer data sets by assigning them the same effect
allele. For all risk factors, mendelian randomization esti-
mates were first generated per individual SNP using the Wald
ratio and standard errors were approximated using the delta
method approximation. A random-effects inverse-variance
weighted meta-analysis was then used to combine individual
SNPs in an instrument. In analyses of drug targets, inverse-
variance weighted models were adjusted for weak linkage dis-
equilibrium (r2 <0.20) between SNPs with reference to the 1000
Genomes Phase 3 reference panel.12 All mendelian random-
ization estimates (odds ratios [ORs] for OCAC analyses and haz-
ard ratios [HRs] for CIMBA analyses) were scaled up from in-
dividual SNP-level effects on LDL cholesterol levels to reflect
the equivalent of a 1-mmol/L (38.7-mg/dL) reduction in LDL
cholesterol levels. HRs for CIMBA analyses were obtained from
survival analyses performed using time to ovarian cancer di-
agnosis as an end point.
Primary analyses were the association of genetically prox-
ied HMG-CoA reductase inhibition with overall and histotype-
specific invasive epithelial ovarian cancer among women in the
general population (OCAC) and epithelial ovarian cancer in
BRCA1/2 mutation carriers (CIMBA). Secondary analyses were
the association of genetically proxied inhibition of NPC1L1 and
PCSK9 and genetically proxied circulating LDL cholesterol with
these ovarian cancer outcomes. Primary and secondary analy-
ses were prespecified.
The relevance mendelian randomization assumption was
tested by generating estimates of the proportion of variance in
each risk factor explained by the instrument (R2) and F statis-
tics. As a convention, an F statistic of at least 10 is indicative of
evidence against weak instrument bias (a reduction in statisti-
cal power to reject the null hypothesis when an instrument ex-
plains only a small proportion of variance in an exposure).13
The exchangeability mendelian randomization assump-
tion was tested by performing co-localization, which exam-
ines whether SNPs associated with 2 traits are likely to share
causal variants with each other.14 This can be used to assess
whether risk factors and disease outcomes are influenced by
distinct causal variants that are in linkage disequilibrium with
each other (genetic confounding). This method generates a co-
localization posterior probability that the same variant is causal
for both traits and a 95% credible set that represents the mini-
mum number of variants having a cumulative posterior prob-
ability greater than 0.95.
The exclusion restriction mendelian randomization
assumption was tested using different methods for the analy-
ses of genetically proxied drug targets and for the LDL cho-
lesterol analyses. This use of different methods is because
some of these methods require that variants used as genetic
instruments are independent of each other, which was not
the case for drug target analyses. In analyses of drug targets,
violations of the exclusion restriction assumption were
tested by examining associations of the genetic instruments
with previously reported ovarian cancer risk factors (age at
menarche, age at natural menopause, body mass index,
genetic liability to endometriosis, ever use of oral contracep-
tives, and smoking initiation).15-19 The presence of an associa-
tion between a drug target instrument and a previously
reported ovarian cancer risk factor could provide evidence of
horizontal pleiotropy (variants influencing 2 or more traits
through independent biological pathways), a violation of the
exclusion restriction criterion. If there was evidence of asso-
ciation of drug target instruments with a risk factor (P < .05),
multivariable analyses were performed to examine associa-
tions between drug targets and ovarian cancer outcomes,
adjusted for genetically proxied risk factors.20 Consistency of
associations between analyses with and without adjustment
for previously reported risk factors would suggest that analy-
ses are unlikely to be substantially biased by horizontal plei-
otropy. In analyses of LDL cholesterol levels, evidence of
horizontal pleiotropy was examined via the following sensi-
tivity analyses: mendelian randomization Egger method,21
weighted median analysis,22 and weighted mode analyses.23
In addition, iterative leave-one-out analyses were performed
to examine whether results were driven by single influential
SNPs in drug target proxies. Extended descriptions of these
sensitivity analyses along with their assumptions are pro-
vided in the Supplement. A schematic overview of genetic
instrument construction, data sources used, and primary and
sensitivity analyses performed is presented in Figure 1.
All statistical tests were 2-sided and a significance thresh-
old was set at P < .05. For analyses of invasive epithelial ovar-
ian cancer histotypes, evidence of heterogeneity of estimates
across subtypes (P value for heterogeneity) was calculated from
a Cochran Q test, where Q is distributed as a χ2 statistic with K
(number of histotypes) – 1 degree of freedom and the percent-
age of variability across these estimates due to heterogeneity
beyond chance was quantified using the I2 statistic.24 A sig-
nificance threshold for evidence of heterogeneity across his-
totypes was set at P <.05.
As sensitivity analyses, Bonferroni corrections were ap-
plied to establish multiple testing–adjusted significance thresh-
olds for the following analyses: overall invasive epithelial ovar-
ian cancer analyses in OCAC (Bonferroni threshold of P < .01
[0.05/4 statistical tests {3 drug targets and LDL cholesterol
tested against 1 ovarian cancer end point}]); epithelial ovar-
ian cancer analyses in CIMBA (Bonferroni threshold of P < .01
[0.05/4 statistical tests {3 drug targets and LDL cholesterol
tested against 1 ovarian cancer end point}]) and invasive epi-
thelial ovarian cancer histotypes in OCAC (Bonferroni thresh-
old of P < .003 [0.05/20 statistical tests {3 drug targets and LDL
cholesterol tested against 5 ovarian cancer histotypes}]). All
statistical analyses were performed using R version 3.3.1.
Results
After exclusion of 1936 participants because of missing geno-
type calls, the OCAC analytic sample included 22 406 women
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with invasive epithelial ovarian cancer and 40 941 control in-
dividuals of European ancestry along with individuals with the
following invasive histotypes: high-grade serous carcinoma
(n = 13 037), low-grade serous carcinoma (n = 1012), endome-
trioid carcinoma (n = 2810), mucinous ovarian cancer
(n = 1417), and clear cell carcinoma (n = 1366). Individuals with
invasive histotypes classified as “other” by OCAC (n = 2764)
were included in analyses for invasive epithelial ovarian can-
cer but were not assessed separately. The median (interquar-
tile range) ages of participants in overall invasive epithelial
ovarian cancer analyses were 59.0 (51.0-67.0) years in the ana-
lytic sample and 57.0 (49.0-65.0) years in the control sample.
Participants were enrolled from 14 countries (the United States,
Australia, Belarus, Germany, Belgium, Denmark, Finland,
Norway, Canada, Poland, the United Kingdom, Spain,
the Netherlands, and Sweden). The CIMBA sample included
3887 women with epithelial ovarian cancer and 27 561 con-
trol individuals of European ancestry. The median (interquar-
tile range) ages at censoring for CIMBA participants were as fol-
lows: 50.0 (45.0-57.0) years in individuals with BRCA1, 57.0
(50.0-63.2) years in individuals with BRCA2, 41.5 (34.1-50.0)
years in BRCA1 control individuals, and 44.7 (36.5-54.0) years
in BRCA2 control individuals. Participants in CIMBA came from
25 countries (including 20 European countries, the United
States, Australia, Canada, Israel, and South Africa). The age
range of participants across studies was 20 to 100 years. There
was no overlap in participants across OCAC and CIMBA analy-
ses. The Global Lipids Genetics Consortium sample consisted
of less than or equal to 196 475 individuals who were primar-
ily of European ancestry (96% of individuals).
Characteristics of genetic variants in HMGCR, NPC1L1, and
PCSK9 used to proxy pharmacological targets are presented
in Table 1. In brief, 5 SNPs in HMGCR (rs12916, rs10515198,
rs12173076, rs3857388, rs7711235) were used to proxy HMG-
CoA reductase inhibition, 3 SNPs in NPC1L1 (rs2073547,
rs217386, rs7791240) proxied NPC1L1 inhibition, and 11 SNPs
Figure 1. Genetic Instrument Construction, Data Sources, and Analysis Plan in a Study of the Association Between Genetically Proxied Inhibition
of HMG-CoA Reductase and Epithelial Ovarian Cancer
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For each drug target or risk factor, genetic instruments were constructed by
obtaining summary genetic association data on single-nucleotide
polymorphisms (SNPs) associated with low-density lipoprotein (LDL)
cholesterol located within or near the gene encoding the drug target
(3-hydroxy-3-methylglutaryl coenzyme A [HMG-CoA] reductase, Niemann-Pick
C1-Like 1 [NPC1L1], proprotein convertase subtilisin/kexin type 9 [PCSK9]) or
independent of genomic position (LDL cholesterol) from Willer et al11
(N = 19 6465). Summary genetic association data for these SNPS were then
extracted from genome-wide association studies of invasive epithelial ovarian
cancer (Ovarian Cancer Association Consortium) and epithelial ovarian cancer in
BRCA1/2 mutation carriers (Consortium of Investigators of Modifiers of
BRCA1/2). After matching SNPs across data sets by assigning them the same
effect allele, mendelian randomization analyses were performed using
inverse-variance weighted random-effects models as primary analyses and
various approaches as sensitivity analyses to test mendelian randomization
assumptions (exchangeability and exclusion restriction). The bottom boxes
represent the use of different sensitivity analyses to test mendelian
randomization assumptions for drug target analyses and LDL cholesterol,
because some of these sensitivity analyses require that variants used as genetic
instruments are independent of each other, which was not the case for drug
target analyses.
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in PCSK9 (rs11591147, rs11206510, rs2479409, rs585131,
rs11206514, rs2495477, rs572512, rs2479394, rs12067569,
rs10493176, rs11583974) proxied PCSK9 inhibition. Effect al-
lele frequencies for SNPs used to proxy drug targets were simi-
lar across GWASs for measured LDL cholesterol levels, inva-
sive epithelial ovarian cancer in the general population (OCAC),
and epithelial ovarian cancer among BRCA1/2 mutation carri-
ers (CIMBA) (eTable 1 in the Supplement). Characteristics of
76 SNPs used to proxy circulating LDL cholesterol levels are
presented in eTable 2 in the Supplement.
Across the 4 risk factors examined, F statistics for their re-
spective genetic instruments (used to examine the relevance
mendelian randomization assumption) ranged from 71.7 to
196.4, suggesting that weak instrument bias was unlikely to
contribute to the analyses. F statistics and power calcula-
tions are presented for each risk factor in eTable 3 in the Supple-
ment.
Primary Analyses
Genetically proxied HMG-CoA reductase inhibition equiva-
lent to a 1-mmol/L (38.7-mg/dL) reduction in LDL cholesterol
was significantly associated with invasive epithelial ovarian
cancer in OCAC (OR, 0.60 [95% CI, 0.43-0.83]; P = .002; Table 2
and Figure 2). This association did not significantly differ
across 5 invasive histotypes assessed (P value for heteroge-
neity = 0.84; I2 = 0.00%). In analyses among BRCA1 and BRCA2
mutation carriers combined in CIMBA, genetically proxied
HMG-CoA reductase inhibition was significantly associated
with epithelial ovarian cancer risk (HR, 0.69 [95% CI, 0.51-
0.93]; P = .01; Figure 3).
Secondary Analyses
Genetically proxied inhibition of NPC1L1 (OR, 0.97 [95% CI,
0.53-1.75]; P = .91) and PCSK9 (OR, 0.98 [95% CI, 0.85-1.13];
P = .80) were not significantly associated with overall or
histotype-stratified ovarian cancer in the OCAC sample
(Table 2 and Figure 2). Although genetically proxied circulat-
ing LDL cholesterol was not significantly associated with
overall ovarian cancer (per 1-mmol/L reduction in LDL cho-
lesterol: OR, 0.98 [95% CI, 0.91-1.05]; P = .55), a 1-mmol/L
reduction in genetically proxied LDL cholesterol was signifi-
cantly associated with invasive mucinous ovarian cancer
(OR, 0.80 [95% CI, 0.65-0.98]; P = .03) in histotype-stratified
analyses. Findings for associations of genetically proxied LDL
cholesterol with overall and histotype-specific ovarian cancer
were largely consistent in sensitivity analyses examining
horizontal pleiotropy (eTable 4 in the Supplement). In analy-
ses among BRCA1/2 mutation carriers in CIMBA, there were
no significant associations of genetically proxied inhibition
of NPC1L1 (HR, 0.95 [95% CI, 0.56-1.61]; P = .84), PCSK9
(HR, 0.92 [95% CI, 0.78-1.08]; P = .31), or genetically proxied
circulating LDL cholesterol levels (HR, 0.96 [95% CI, 0.90-
1.03]; P = .24) with epithelial ovarian cancer HR.
Sensitivity Analyses
In sensitivity analyses applying a Bonferroni correction to ac-
count for multiple testing across overall invasive epithelial
ovarian cancer analyses in OCAC (P < .01), the association of
genetically proxied HMG-CoA reductase inhibition with inva-
sive epithelial ovarian cancer (P = .002) remained signifi-
cant. When correcting for multiple tests performed across







Frequencyb Effect (95% CI), mmol/L P Value
HMGCR
rs12916 T/C 0.57 −0.073 (−0.081 to −0.065) 7.8 × 10−78
rs10515198 G/A 0.90 −0.060 (−0.072 to −0.048) 6.0 × 10−22
rs12173076 T/G 0.88 −0.065 (−0.077 to −0.053) 2.3 × 10−27
rs3857388 T/C 0.87 −0.042 (−0.054 to −0.030) 2.2 × 10−11
rs7711235 A/G 0.73 −0.038 (−0.050 to −0.026) 5.0 × 10−10
NPC1L1
rs2073547 A/G 0.81 −0.049 (−0.059 to −0.039) 1.9 × 10−21
rs217386 A/G 0.41 −0.036 (−0.044 to −0.028) 1.2 × 10−19
rs7791240 T/C 0.91 −0.043 (−0.057 to −0.029) 1.8 × 10−10
PCSK9
rs11591147 T/G 0.02 −0.497 (−0.532 to −0.462) 8.6 × 10−143
rs11206510 C/T 0.15 −0.083 (−0.093 to −0.073) 2.4 × 10−53
rs2479409 A/G 0.67 −0.064 (−0.072 to −0.056) 2.5 × 10−50
rs585131 C/T 0.18 −0.064 (−0.074 to −0.054) 2.7 × 10−35
rs11206514 C/A 0.39 −0.051 (−0.059 to −0.043) 1.0 × 10−32
rs2495477 G/A 0.40 −0.064 (−0.074 to −0.054) 7.3 × 10−30
rs572512 C/T 0.65 −0.048 (−0.058 to −0.038) 5.3 × 10−26
rs2479394 A/G 0.72 −0.039 (−0.047 to −0.031) 1.6 × 10−19
rs12067569 G/A 0.97 −0.089 (−0.109 to −0.069) 2.0 × 10−17
rs10493176 G/T 0.11 −0.078 (−0.098 to −0.058) 2.5 × 10−14
rs11583974 G/A 0.97 −0.065 (−0.089 to −0.041) 4.0 × 10−09
SI conversion: To convert mmol/L to
mg/dL, multiply by 38.7.
a Low-density lipoprotein (LDL)
cholesterol–lowering allele; effect
represents the change in LDL
cholesterol levels (mmol/L) per
copy of the effect allele.
b Estimates were obtained from the
1000 Genomes Phase 3 panel
(European samples);
single-nucleotide polymorphisms to
act as genetic proxies for drug
targets were obtained within a 100
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analyses examining epithelial ovarian cancer among BRCA1/2
mutation carriers in CIMBA (P < .01), the association of ge-
netically proxied HMG-CoA reductase inhibition with epithe-
lial ovarian cancer (P = .01) was no longer significant. Like-
wise, when applying a Bonferroni correction to multiple tests
performed across invasive epithelial ovarian cancer histo-
types in OCAC (P < .003), the associations of genetically prox-
ied HMG-CoA reductase inhibition with endometrioid carci-
noma (P = .01) and genetically proxied LDL cholesterol levels
with invasive mucinous ovarian cancer (P = .03) were no lon-
ger significant.
Tests of Mendelian Randomization Assumptions
As a test for the exchangeability mendelian randomization
assumption, co-localization analysis found evidence for
co-localization of 1 variant (rs7703051) within HMGCR
(co-localization posterior probability = 0.014) and generated
a 95% credible set that incorporated 2 additional variants in
perfect or near-perfect linkage disequilibrium with this vari-
ant (rs11749783 [r2 = 1.00] and rs3846663 [r2 = 0.98])
(eTable 5 in the Supplement). This top co-localized variant
(rs7703051) was also in strong linkage disequilibrium with
rs12916 (r2 = 0.92). Analyses examining associations of the
top co-localized variant were consistent with primary analy-
ses for ovarian cancer in OCAC (OR, 0.58 [95% CI, 41-0.84])
and in BRCA1/2 mutation carriers in CIMBA (HR, 0.69 [95%
CI, 0.50-0.95]).
When testing associations of the genetic instrument for
HMG-CoA reductase with ovarian cancer risk factors (exami-
nation of the exclusion restriction mendelian randomization
assumption), there was evidence for an association of this in-
strument with age at menarche (change in age at onset per
1-mmol/L reduction in LDL cholesterol, −0.18 [95% CI, −0.33
to −0.03l]; P = .02) and body mass index (change in body mass
index per 1-mmol/L reduction in LDL cholesterol, 0.20 [95%
CI, 0.06-0.34]; P = .006) (eTable 6 in the Supplement). Mul-
tivariable mendelian randomization analyses adjusting for the
association of these factors with epithelial ovarian cancer were
consistent with results obtained in primary analyses among
women in OCAC and in BRCA1/2 mutation carriers in CIMBA
(eTable 7 in the Supplement). Additionally, results of analy-
ses that iteratively removed 1 SNP at a time from the instru-
ment and recalculated the overall mendelian randomization
estimate were consistent, suggesting that associations were not
Table 2. Association Between Genetically Proxied Inhibition of 3-Hydroxy-3-Methylglutaryl Coenzyme A
(HMG-CoA) Reductase, Niemann-Pick C1-Like 1 (NPC1L1), and Proprotein Convertase Subtilisin/Kexin Type 9
(PCSK9) and Genetically Proxied LDL Cholesterol Levels and Overall and Histotype-Specific Invasive
Epithelial Ovarian Cancer Among Women in the General Population
Outcome Cases, No. Odds Ratio (95% CI)a P Value
HMG-CoA Reductase
Invasive epithelial ovarian cancer 22 406 0.60 (0.43-0.83) .002
High-grade serous carcinoma 13 037 0.70 (0.47-1.04) .08
Low-grade serous carcinoma 1012 1.49 (0.22-10.05) .68
Mucinous carcinoma 1417 0.53 (0.12-2.42) .41
Endometrioid carcinoma 2810 0.40 (0.19-0.83) .01
Clear cell carcinoma 1366 0.61 (0.19-1.92) .40
NPC1L1
Invasive epithelial ovarian cancer 22 406 0.97 (0.53-1.75) .91
High-grade serous carcinoma 13 037 0.93 (0.46-1.88) .83
Low-grade serous carcinoma 1012 0.34 (0.04-2.93) .33
Mucinous carcinoma 1417 1.39 (0.23-8.24) .72
Endometrioid carcinoma 2810 1.62 (0.44-5.92) .47
Clear cell carcinoma 1366 0.43 (0.07-2.55) .35
PCSK9
Invasive epithelial ovarian cancer 22 406 0.97 (0.81-1.16) .74
High-grade serous carcinoma 13 037 0.87 (0.79-1.20) .82
Low-grade serous carcinoma 1012 1.21 (0.65-2.25) .55
Mucinous carcinoma 1417 0.99 (0.58-1.66) .96
Endometrioid carcinoma 2810 0.87 (0.55-1.39) .57
Clear cell carcinoma 1366 1.05 (0.61-1.83) .86
LDL Cholesterol
Invasive epithelial ovarian cancer 22 406 0.98 (0.91-1.05) .55
High-grade serous carcinoma 13 037 1.00 (0.92-1.09) .99
Low-grade serous carcinoma 1012 1.05 (0.85-1.29) .68
Mucinous carcinoma 1417 0.80 (0.65-0.98) .03
Endometrioid carcinoma 2810 0.92 (0.78-1.10) .36
Clear cell carcinoma 1366 1.01 (0.85-1.21) .90
a The exponential change in odds of
invasive epithelial ovarian cancer
per genetically proxied inhibition of
drug target equivalent to a
1-mmol/L (38.7-mg/dL) decrease in
low-density lipoprotein (LDL)
cholesterol or the exponential
change in odds of invasive epithelial
ovarian cancer per genetically
proxied 1-mmol/L decrease in LDL
cholesterol. Invasive histotypes
classified as “other” by Ovarian
Cancer Association Consortium
(n = 2764) were included in
analyses for invasive epithelial
ovarian cancer but were not
assessed separately. In
histotype-stratified analyses, there
was no statistically significant
evidence of heterogeneity across
the 5 histotypes assessed (P value
for heterogeneity = .84;
I2 = 0.00%). The P value for
heterogeneity was calculated from
a Cochran Q statistic where Q is
distributed as a χ2 statistic with K
(number of histotypes) – 1 degrees
of freedom.
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being driven through individual influential SNPs (eTable 8 in
the Supplement).
Discussion
In this mendelian randomization analysis of 22 406 women
with invasive epithelial ovarian cancer and 40 941 control
individuals, lifelong naturally randomized genetically
proxied inhibition of HMG-CoA reductase was significantly
associated with lower odds of ovarian cancer. Similar asso-
ciations were observed when analyses were restricted to
BRCA1/2 mutation carriers. There were no significant asso-
ciations of genetically proxied NPC1L1 or PCSK9 inhibition
or LDL cholesterol levels with epithelial ovarian cancer in
the general population or among BRCA1/2 mutation carriers,
supporting a possible mechanism-specific effect of HMG-
CoA reductase inhibition.
Findings for HMG-CoA reductase inhibition and epithe-
lial ovarian cancer are consistent with results from labora-
tory and most epidemiological studies. Statins have been
shown to have antiproliferative and anti-invasive properties
in cell lines and animal models of ovarian cancer.4-6 A meta-
analysis of 5 observational studies with 624 ovarian cancer
cases reported that statin use was significantly associated with
a lower risk of ovarian cancer (relative risk, 0.79 [95% CI, 0.64-
0.98]) with no significant evidence of heterogeneity across
studies (P value for heterogeneity = 0.67; I2 = 0.0%).8 Two sub-
sequent case-control studies yielded conflicting findings; a
Danish registry-based analysis of 4103 individuals with epi-
thelial ovarian cancer and 58 706 control individuals re-
ported no significant evidence of an association between ever
use of statins and cancer risk (OR, 0.98 [95% CI, 0.87-1.10]),
but an analysis of the New England Case Control study (2040
individuals with epithelial ovarian cancer and 2100 control in-
dividuals) showed a significantly lower odds of ovarian can-
cer in women who self-reported statin use compared with non-
users (OR, 0.68 [95% CI, 0.54-0.85]).7,25
It has been hypothesized that the principal mechanism of
a putative protective effect of statins on cancer is through pro-
longed lowering of circulating cholesterol levels which, in turn,
modulates hyperplastic growth and neoplasia.26 The lack of
association of genetically proxied inhibition of NPC1L1 and
PCSK9 along with genetically proxied LDL cholesterol levels
suggests that circulating cholesterol may not be driving the ob-
served association of HMG-CoA reductase inhibition with ovar-
ian cancer. The inhibition of mevalonate synthesis by HMG-
CoA reductase inhibition in the cholesterol biosynthesis
pathway has downstream consequences on various products
in this pathway, including levels of steroid precursors, some
of which have been implicated in ovarian cancer risk.27,28
The number of BRCA1 and BRCA2 mutation samples in the
current study was too small to examine associations of phar-
macological targets and LDL cholesterol with epithelial ovar-
ian cancer stratified across common histotypes in these analy-
ses; however, previous studies have demonstrated that the
Figure 2. Mendelian Randomization Estimates of the Association Between 3-Hydroxy-3-Methylglutaryl
Coenzyme A (HMG-CoA) Reductase, Niemann-Pick C1-Like 1 (NPC1L1), and Proprotein Convertase
Subtilisin/Kexin Type 9 (PCSK9) With Invasive Epithelial Ovarian Cancer Among Women in the General Population
P Value
0.2 31
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majority of cases in these populations are high-grade serous
carcinoma.29 Women with mutations in BRCA1 have an esti-
mated lifetime risk of ovarian cancer of 44% and women with
mutations in BRCA2 have an estimated lifetime risk of 17%.30,31
Risk-reducing salpingo-oophorectomy is recommended for
ovarian cancer prevention in these high-risk groups. How-
ever, adverse events associated with early-onset surgical meno-
pause, including increased cardiovascular, osteoporotic, and
overall mortality risks and potential deleterious effects on qual-
ity of life, discourage approximately 30% of BRCA1/2 muta-
tion carriers from having this procedure.31-33
Strengths of this analysis include the use of genetic vari-
ants within genes that encode drug targets to proxy the po-
tential effect of commonly prescribed LDL cholesterol–
lowering therapies, which should minimize confounding and
avoids reverse causation bias; the use of summary genetic as-
sociation data, which permitted the exploitation of relatively
precise estimates of SNP exposure and SNP outcome associa-
tions from several large GWAS meta-analyses of lipids and ovar-
ian cancer, allowing statistical power and precision of analy-
ses to be increased; and the combination of multiple variants
into genetic proxies, allowing the proportion of variance in drug
targets explained by instruments to be increased.
Co-localization was used as a sensitivity analysis to test
whether the association of genetically proxied HMG-CoA re-
ductase with ovarian cancer reflected both of these traits being
influenced by 1 or more shared causal variants or whether each
trait is influenced by distinct causal variants that are in link-
age disequilibrium with each other (ie, genetic confounding).
Findings from co-localization analysis suggested that both
HMG-CoA reductase and ovarian cancer shared a causal vari-
ant within the HMGCR locus, providing some evidence against
genetic confounding accounting for the association between
these traits. Multivariable mendelian randomization was used
to test whether the association of HMG-CoA reductase inhi-
bition with ovarian cancer was biased through horizontal plei-
otropy by adjusting models for genetically proxied risk fac-
tors that have previously been linked to ovarian cancer. The
consistency of associations of HMG-CoA reductase inhibition
with ovarian cancer in models with and without adjustment
for previously reported ovarian cancer risk factors suggested
that findings were unlikely to be biased by horizontal pleiot-
ropy through these risk factors. Therefore, results from sen-
sitivity analyses that tested for potential confounding (co-
localization) and pleiotropic effects (multivariable mendelian
randomization) suggest that the findings of this study are com-
patible with a causal relationship between HMG-CoA reduc-
tase inhibition and ovarian cancer. However, the mendelian
randomization approach used in this analysis cannot estab-
lish whether modulation of HMG-CoA reductase via drug treat-
ment would reduce risk of ovarian cancer; establishing cau-
sality would require a randomized clinical trial.
Extension of the analyses presented in this study to a sur-
vival framework among women diagnosed with ovarian can-
cer could inform on the potential treatment efficacy of stat-
ins for ovarian cancer progression and survival. In addition,
Figure 3. Mendelian Randomization Estimates of the Association Between 3-Hydroxy-3-Methylglutaryl
Coenzyme A (HMG-CoA) Reductase, Niemann-Pick C1-Like 1 (NPC1L1), and Proprotein Convertase
Subtilisin/Kexin Type 9 (PCSK9) With Epithelial Ovarian Cancer Among BRCA1/2 Mutation Carriers
P Value
0.2 31
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the design of randomized clinical trials within high-risk popu-
lations (BRCA1/2 mutation carriers and/or women at high poly-
genic risk) would be necessary to provide evidence for a role
of statin use in ovarian cancer prevention in these groups.
Limitations
This study has several limitations. First, direct measures of drug
targets to generate estimates of ovarian cancer risk reduc-
tions per unit change in function of these targets were not avail-
able. Consequently, estimates were scaled to represent reduc-
tions in LDL cholesterol levels under the assumption that drug
target inhibition is proportional to LDL cholesterol lowering.
Second, effect estimates for associations of SNPs with drug tar-
gets and LDL cholesterol along with estimates of genetic in-
strument strength for these risk factors within ovarian can-
cer data sets were derived from analyses performed in an
independent GWAS of lipid levels in up to 196 475 individuals
primarily of European ancestry. Effect estimates and mea-
sures of instrument strength can be transported across data
sets under the condition that all data sets are representative
of the same underlying population (the basis of the 2-sample
mendelian randomization approach used in this analysis).
Third, statistical power was limited to detect associations
with less common invasive histotypes (low-grade serous,
mucinous, and clear cell carcinomas), although there was
no statistically significant evidence for heterogeneity of asso-
ciations of drug targets across all subtypes assessed. Fourth,
the analyses presented assume no interaction of the associa-
tion of genetic proxies for drug targets and ovarian cancer
(eg, gene-environment, gene-gene) and linear associations
of drug target inhibition with cancer risk. Fifth, while these
analyses did not account for previously reported associations
of genetically proxied LDL cholesterol with lipid-lowering drug
use in this analysis, such correction would be expected
to strengthen, rather than attenuate, findings presented in
this study. Sixth, the Bonferroni correction applied to
multiple tests performed in sensitivity analyses suggests that
some findings may represent false-positive findings. Sev-
enth, if statin treatment were to lower the risk of ovarian can-
cer, the magnitude of risk lowering achieved through taking
statins may not correspond to the effect size observed in this
analysis. This is because mendelian randomization estimates
represent the long-term modulation of drug targets on dis-
ease risk and therefore may suggest larger risk reductions per
unit change in drug target compared with those obtained from
drug administration over a relatively shorter duration. Eighth,
findings among BRCA1/2 mutation carriers cannot be consid-
ered a replication of findings among women in the general
population because of important clinical, histopathological,
and molecular differences between hereditary and sporadic
ovarian cancers.34 Ninth, valid causal inference in mendelian
randomization analyses relies on several assumptions, some
of which are not verifiable (ie, exchangeability and exclusion
restriction assumptions). While the findings of this study were
consistent in various sensitivity analyses testing these assump-
tions, the possibility that these findings were biased through
confounding and/or horizontal pleiotropy cannot be defini-
tively ruled out.
Conclusions
Genetically proxied inhibition of HMG-CoA reductase was
significantly associated with lower odds of epithelial ovarian
cancer. However, these findings do not indicate risk reduc-
tion from medications that inhibit HMG-CoA reductase;
further research is needed to understand whether there is
a similar association with such medications.
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